伊班膦酸钠联合化疗对乳腺癌骨转移的临床疗效

Therapeutic Effect of Ibandronate Combined with Chemotherapy On Bone Metastases of Advanced Breast Cancer

目的观察伊班膦酸钠(艾本)联合化疗对乳腺癌骨转移的止痛效果和不良反应.方法将65例晚期乳腺癌并骨转移患者随机分为A、B 2个组,A组给予伊班膦酸钠4 mg,静脉滴注,每4周1次,连用2～4次,并给长春瑞宾25 mg/m2,静脉注射,第1、8天;表阿霉素50～70 mg/m2,静脉注射,第2天;每21～28天为1个周期,连用2～4个周期.B组为单用伊班膦酸钠,剂量和用法同A组.结果A、B 2组止痛有效率分别为87.5%(28/32)和81.3%(26/32),经统计学分析,元显著性差异(P＞0.05);A组不良反应较B组多,主要是化疗后骨髓抑制及消化道反应.结论对乳腺癌骨转移性疼痛,采用伊班膦酸钠治疗,可获得较好的疗效,若再加化疗,并不能进一步提高近期镇痛效果.

Objective To evaluate therapeutic effect and adverse effect of ibandronate combined with chemotherapy in breast cancer patients with bone metastases. Methods 65 patients with advanced breast cancer and bone metastases were randomly assigned to received ibandronate combined with chemotherapy of Epirubicin and Vinorelbine （group A）, or receive ibandronate alone （group B）.Results Overall response rate of pain relief was 87.5% （28/32） and 81.3% （26/32） in group A and B,showing no significant difference （P〈0.05）between the two groups. There were more adverse effects in group A than in group B. Most of them were medulla regression,gastrointestinal reaction. Conclusion Ibandronate have a satisfactory pain relief effect in patients with advanced breast cancer and bone metastases. The effect can＇t be enhanced when ibandronate combined with chemotherapy is used.